Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: Case report

Canadian Journal of Ophthalmology

Volumn 51, Issue 1, 2016, Pages e4-e6

  Basilious, Alfred ^a   Lloyd, John C ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; HOMATROPINE; PEMBROLIZUMAB; PREDNISOLONE ACETATE; STEROID; TRIAMCINOLONE ACETONIDE; ANTINEOPLASTIC AGENT; GLUCOCORTICOID; MONOCLONAL ANTIBODY;

ADULT; ANTERIOR EYE CHAMBER; BEST CORRECTED VISUAL ACUITY; BLURRED VISION; CASE REPORT; CATARACT EXTRACTION; CORNEA THICKNESS; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOTONY MACULOPATHY; INTRAOCULAR PRESSURE; IRIDOCYCLITIS; LETTER; MELANOMA; MIDDLE AGED; PEMBROLIZUMAB INDUCED UVEITIS; PHOTOSENSITIVITY; RETINA MACULA CYSTOID EDEMA; SUBCAPSULAR CATARACT; TONOMETRY; TOPOGRAPHY; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; VITREOUS FLOATERS; CATARACT; CHEMICALLY INDUCED; OCULAR HYPOTENSION; OPTICAL COHERENCE TOMOGRAPHY; SECONDARY; UVEITIS, ANTERIOR;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CATARACT; CATARACT EXTRACTION; FEMALE; GLUCOCORTICOIDS; HUMANS; MELANOMA; MIDDLE AGED; OCULAR HYPOTENSION; TOMOGRAPHY, OPTICAL COHERENCE; UVEITIS, ANTERIOR;

EID: 84963506978     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2015.09.008     Document Type: Letter

References (9)

1. 1 Robert, C., Ribas, A., Wolchok, J.D., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384 (2014), 1109–1117.
2. 2 Francisco, L.M., Sage, P.T., Sharpe, A.H., The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236 (2010), 219–242.
3. 3 Blank, C., Brown, I., Peterson, A.C., et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 64 (2004), 1140–1145.
4. 4 Okazaki, T., Honjo, T., PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 19 (2007), 813–824.
5. 5 Topalian, S.L., Hodi, F.S., Brahmer, J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
6. 6 Hamid, O., Robert, C., Daud, A., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369 (2013), 134–144.
7. 7 Manusow, J.S., Khoja, L., Pesin, N., Joshua, A.M., Mandelcorn, E.D., Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma. J Immunother Cancer, 2, 2014, 41.
8. 8 Robinson, M.R., Chan, C.-C., Yang, J.C., et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother 27 (2004), 478–479.
9. 9 Daniel, E., Pistilli, M., Pujari, S.S., et al. Risk of hypotony in noninfectious uveitis. Ophthalmology 119 (2012), 2377–2385.